Mizolastine in primary acquired cold urticaria

Area of Science:

• Dermatology
• Allergology
• Pharmacology

Background:

• Primary acquired cold urticaria (CU) presents treatment challenges due to variable efficacy and side effects of conventional antihistamines.
• The need for effective and safe treatments for CU is significant.

Purpose of the Study:

• To evaluate the efficacy and safety of mizolastine, an antihistamine with antiallergic properties, compared to placebo in patients with primary acquired CU.
• To assess mizolastine's impact on cold-induced wheal reactions and pruritus.

Main Methods:

• A phase II, multicenter, randomized, double-blind, crossover, placebo-controlled study involving 28 patients with primary acquired CU.
• Mizolastine (10 mg, once daily) was administered and compared against a placebo.
• Efficacy was assessed using the cold-stimulation time test, wheal response measurements, and pruritus intensity following an ice-cube challenge.

Main Results:

• Mizolastine demonstrated a statistically significant delay in the cold-induced wheal reaction (P =.006).
• Significant reductions in wheal response at 3 and 10 minutes (P =.015, P =.009) and pruritus intensity (P =.005) were observed with mizolastine compared to placebo.
• No clinically relevant adverse events were reported during the study.

Conclusions:

• Mizolastine (10 mg, once daily) is superior to placebo in managing primary acquired cold urticaria.
• The drug effectively delays and reduces cold-induced wheal reactions without significant safety concerns.
• Mizolastine shows promise as an effective therapeutic option for cold urticaria treatment.